VetStem founder and CEO, Dr. Bob Harman, was recently featured on a San Diego-based podcast to discuss all things stem cells, including the current COVID-19 clinical trial developed by our human company, Personalized Stem Cells.

One Medicine: Animal Data Helping People

We have previously blogged about a concept we call “One Medicine,” also known as translational medicine, in which advances in the veterinary field lead to advances in human medicine. In the last year, this notion has really come to the forefront, as we were hit with the COVID-19 pandemic.

It is very common for human scientists and doctors to review data obtained from animals when developing a new drug or technology. In a previous blog, we discussed how animal data was utilized to expedite development of a COVID-19 vaccine. Additionally, evaluation of COVID-19 positive animals has helped researchers understand how the virus functions and how it is transmitted in various species.

Data from VetStem Patients Helps People with COVID-19

VetStem has also joined the ranks in the fight against COVID-19. In fact, it was VetStem’s 15+ years of veterinary stem cell data that led to the development of an FDA approved COVID-19 stem cell clinical trial in human patients. Our human stem cell company, Personalized Stem Cells, Inc., developed and received FDA approval for the clinical trial and then licensed it to Sorrento Therapeutics. The study is well underway and the preliminary results look very promising.

In addition to discussing our contributions to the COVID-19 clinical trial, Dr. Harman also discussed our work with exotics organizations and specifically mentions helping an arthritic Sun Bear at the San Diego Zoo. He gives a bit of history regarding VetStem’s formation, treating his border collie Ben, as well as his own treatment with stem cell therapy for a rotator cuff injury.

Click here to listen to the podcast!